Actively Recruiting
Phase 12 Study Evaluating Safety and Effects of Oral AVZO-023 Alone or With AVZO-021 and Endocrine Therapy in Advanced Solid Tumors
Led by Avenzo Therapeutics, Inc. · Updated on 2026-08-10
380
Participants Needed
16
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying AVZO-023, an oral drug that selectively inhibits CDK4, to evaluate its safety, tolerability, how it is processed in the body, the highest dose tolerated, and its effects against advanced solid tumors, particularly hormone receptor positivehuman epidermal growth factor receptor 2 negative HRHER2- breast cancer. This is a Phase 12 trial involving patients with advanced or metastatic breast cancer, aiming to find the best dose and assess preliminary antitumor activity. The study involves several treatment groups AVZO-023 alone or combined with AVZO-021, a selective CDK2 inhibitor, with or without endocrine therapies such as fulvestrant or letrozole. Participants receive oral doses in 28-day cycles, with doses gradually increased in Phase 1 to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2 evaluates antitumor activity using these combinations at the recommended doses. Participants will be closely monitored through laboratory tests, molecular and tumor sample collection, and imaging assessments to measure tumor response and safety outcomes. Researchers will track dose-limiting toxicities, adverse events, pharmacokinetics, and antitumor effects over approximately two years, with some long-term survival follow-up up to around 76 months. The total study duration extends until 2030, with ongoing treatment cycles and evaluations according to protocol.
CONDITIONS
Brief Title
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Research Team
M
Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here